Almac Embarking on Study to ID Prognostic Lung Cancer Signature | GenomeWeb
NEW YORK (GenomeWeb News) – Northern Ireland-based translational genomics company Almac Diagnostics announced today that it is embarking on an international, multi-center collaborative lung cancer study aimed at finding a prognostic gene expression signature for patients with early non-small cell lung cancer, the most common form of lung cancer.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.